Catalyst Pharmaceuticals Inc $ 5.43 0.18 (3.43%)
Volume:
225,842
Avg Vol (1m):
2,557,920
Market Cap $:
546.04 Mil
Enterprise Value $:
487.21 Mil
P/E (TTM):
0.00
P/B:
8.89
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
|
Price: $5.43 | ||
Manual of Stocks™ Web
Financial Strength | 7.8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 55.02 | ||
| Equity-to-Asset | 0.81 | ||
| Debt-to-Equity | 0.02 | ||
| Debt-to-EBITDA | -0.08 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 19.91 | ||
| Beneish M-Score | 84.51 | ||
| WACC vs ROIC | |||
Profitability | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -31.24 | ||
| Net Margin % | -28.78 | ||
| ROE % | -20.01 | ||
| ROA % | -17.59 | ||
| ROC (Joel Greenblatt) % | -1868.2 | ||
| 3-Year EBITDA Growth Rate | -10.9 | ||
| 3-Year EPS without NRI Growth Rate | -9.7 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Forward PE Ratio | 9.53 | ||
| PB Ratio | 8.89 | ||
| PS Ratio | 13.34 | ||
| EV-to-EBIT | -37.32 | ||
| EV-to-EBITDA | -37.44 | ||
| EV-to-Revenue | 11.66 | ||
| Current Ratio | 5.09 | ||
| Quick Ratio | 5.07 | ||
| Days Inventory | 5.17 | ||
| Days Sales Outstanding | 90.63 | ||
| Days Payable | 203.4 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.5 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 8.85 | ||
| Price-to-Median-PS-Value | 0.2 | ||
| Earnings Yield (Greenblatt) % | -2.68 |